5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter
Purpose. General use of nucleoside analogues in the treatment of viral infections and cancer is often limited by poor oral absorption. Valacyclovir, a water soluble amino acid ester prodrug of acyclovir has been reported to increase the oral bioavailability of acyclovir but its absorption mechanism is unknown. This study characterized the intestinal absorption mechanism of 5′-amino acid ester prodrugs of the antiviral drugs and examined the potential of amino acid esters as an effective strategy for improving oral drug absorption.
Methods. Acyclovir (ACV) and Zidovudine (AZT) were selected as the different sugar-modified nucleo-side antiviral agents and synthesized to L-valyl esters of ACV and AZT (L-Val-ACV and L-Val-AZT), D-valyl ester of ACV (D-Val-ACV) and glycyl ester of ACV (Gly-ACV). The intestinal absorption mechanism of these 5′-amino acid ester prodrugs was characterized in three different experimental systems; in siturat perfusion model, CHO/hPEPTl cells and Caco-2 cells.
Results. Testing 5′-amino acid ester prodrugs of acyclovir and AZT, we found that the prodrugs increased the intestinal permeability of the parent nucleoside analogue 3- to 10-fold. The dose- dependent permeation enhancement was selective for the L-amino acid esters. Competitive inhibition studies in rats and in CHO cells transfected with the human peptide transporter, hPEPTl, demonstrated that membrane transport of the prodrugs was mediated predominantly by the PEPT1 H+/dipeptide cotransporter even though these prodrugs did not possess a peptide bond. Finally, transport studies in Caco-2 cells confirmed that the 5′-amino acid ester prodrugs enhanced the transcellular transport of the parent drug.
Conclusions. This study demonstrates that L-amino acid-nucleoside chimeras can serve as prodrugs to enhance intestinal absorption via the PEPT1 transporter, providing a novel strategy for improving oral therapy of nucleoside drugs.
Unable to display preview. Download preview PDF.
- 1.P. de Miranda and M. R. Blum. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12(suppl B):29-37 (1983).Google Scholar
- 4.E. Walter, T. Kissel, and G. L. Amidon. The intestinal peptide carrier: A potential transport system for small peptide derived drugs. Adv. Drug Del. Rev. 20:33-58 (1996).Google Scholar
- 5.J. P. F. Bai, B. H. Stewart, and G. L. Amidon. Gastrointestinal Transport of Peptide and Protein Drugs and Prodrugs. Handbk. Exp. Pharmacol. 110:189-206 (1994).Google Scholar
- 8.P. L. Smith, E. P. Eddy, C.-P. Lee, and G. Wilson. Exploitation of the intestinal oligopeptide transporter to enhance drug absorption. Drug. Del. 1:103-111 (1993).Google Scholar
- 9.M. Hu, P. Subramanian, H. I. Mosberg, and G. L. Amidon. Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa. Pharm. Res. 6:66-70 (1989).PubMedGoogle Scholar
- 11.L. M. Beauchamp, G. F. Orr, P. de Miranda, T. Burnette, and T. A. Krenitsky. Amino acid ester prodrugs of acyclovir. Antiviral. Chem. Chemother. 3:157-164 (1992).Google Scholar
- 14.G. J. Marks, F. M. Ryan, I. J. Hidalgo, and P. L. Smith. Mannitol as a marker for intestinal integrity in in vitroabsorption studies. Gastroenterology 100:A697 (1991).Google Scholar
- 16.A. De Lean, P. J. Munson, and D. Rodbard. Simultaneous analysis of families of sigmoidgand assay and physiological dose-response curves. Am. J. of Physio. 235:E 97-102 (1978).Google Scholar
- 26.H. Bundgaard. Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, in Design of Prodrugs, H. Bundgaard, Ed. (Elsevier, Amsterdam, The Netherlands), pp. 1-92 (1995).Google Scholar